AdvaMed-Chair Exit Interview: Vince Forlenza On Medtech Policy Priorities

BD CEO Vince Forlenza just finished his two-year term as board chairman of AdvaMed. For the most part, his successor will face the same priorities he did during his tenure: repealing the 2.3 percent medical device excise tax and reauthorizing device user fees. Forlenza spoke with Medtech Insight in this podcast interview.